Abstract 2264P
Background
Current precision medicine strategies for non-small-cell lung cancer (NSCLC) rely on individual mutation analyses, evaluation of the tumor mutational burden or specific marker expression (e.g., PD-L1). However, many patients either do not have a suitable targeted treatment or do not respond to the prescribed therapy. Phenotypic proteomic profiling facilitates the understanding of cancer biology beyond genomics. Furthermore, the more rapid targeted proteomics methods may serve as a tool for patient stratification based on proteomic signatures of the tumors.
Methods
We used our previously published resource describing the proteome landscape of 141 NSCLC tumors ( Lehtiö et al. 2021 ) to identify biomarkers of the six observed proteomic subtypes. Namely, we applied a machine learning-based algorithm to proteome-wide peptide-level data to select peptide biomarkers for NSCLC subtype classification. We also applied quality control criteria to select peptides suitable for rapid analysis using a targeted proteomics, parallel reaction monitoring (PRM), method. Therewith, we are currently developing a PRM assay for identifying and quantifying the selected biomarkers in clinical samples such as resected tumors and biopsies. The initial cohort of 141 NSCLC tumors will then be re-analyzed to train a model for subtype prediction.
Results
We identified 200 peptide biomarkers from 174 proteins representing the six proteomic subtypes of NSCLC. Upon cross validating the classifier, we achieved a high average accuracy of 87%. We then acquired heavy isotope-labeled versions of the peptides for absolute quantification of the biomarkers. Our PRM method analyzing the peptide panel quantifies proteomic biomarkers more accurately and reproducibly than other existing proteomics methods. Furthermore, our classification algorithm converts the quantitative data into categorical NSCLC subtype information.
Conclusions
We developed a first-of-its-kind proteomics assay that provides multifactorial characterization of NSCLC tumors covering histology, immune landscape, and oncogenic driver pathways. Our method enables the use of proteomics in a clinical setting and the resultant data may be used for patient stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Karolinska Institutet.
Disclosure
G. Mermelekas, L. Orre: Financial Interests, Personal, Stocks/Shares: FenoMark Diagnostics. J. Lehtiö: Financial Interests, Personal, Stocks/Shares: FenoMark Diagnostics; Financial Interests, Institutional, Research Grant, Not related to the presented work: AstraZeneca, Roche, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08